4,5-Diethyl-3'-ethoxy-pyroflavone

4,5-Diethyl-3'-ethoxy-pyroflavone is a flavone-class polyphenol isolated from Vitex negundo that exhibits dose-dependent antifilarial activity in preclinical bioassays, likely through mechanisms common to flavonoid interference with parasite metabolic processes. All available evidence derives from in vitro and early preclinical studies attributed to Rana et al., with no human clinical data quantifying effect size, therapeutic dose, or safety margin.

Origin & History

4,5-Diethyl-3'-ethoxy-pyroflavone is a naturally occurring flavone isolated from Vitex negundo (Nirgundi), a large aromatic shrub native to tropical and subtropical regions of Asia and Africa, including the Indian subcontinent, Southeast Asia, and East Africa. The parent plant thrives in dry, open wastelands, riverbanks, and forest margins, tolerating poor soils and semi-arid conditions up to elevations of approximately 1500 meters. Vitex negundo has been cultivated and wildcrafted for millennia in Ayurvedic and traditional Chinese medicine, with this specific flavone identified as a minor phytochemical constituent isolated from the plant's leaves, seeds, and roots through solvent extraction and chromatographic fractionation.

Historical & Cultural Context

Vitex negundo, the source plant of this compound, occupies a prominent place in Ayurvedic medicine under the Sanskrit name 'Nirgundi,' with documented use in classical texts including Charaka Samhita and Sushruta Samhita for conditions ranging from inflammatory joint disease and fever to parasitic infections and neurological disorders. In traditional Southeast Asian and Chinese medicine (where the plant is known as Huang Jing or Man Jing Zi in related species), leaf poultices and root decoctions were employed for pain relief, anthelmintic purposes, and skin diseases. The specific isolation of 4,5-diethyl-3'-ethoxy-pyroflavone represents a modern phytochemical effort to identify the active constituents responsible for the antifilarial folk uses of Vitex negundo in endemic regions of South Asia, where lymphatic filariasis caused by Wuchereria bancrofti and Brugia malayi has been a major public health burden. This compound itself carries no independent traditional use history, as its identification as a discrete chemical entity is a product of contemporary analytical chemistry rather than historical ethnobotanical knowledge.

Health Benefits

- **Antifilarial Activity**: Demonstrates dose-dependent lethal or immobilizing effects against filarial parasites in preclinical assays; the precise effective concentration has not been formally published with quantified IC50 or LD50 values in peer-reviewed literature to date.
- **Source-Plant Anti-inflammatory Potential**: Isolated from Vitex negundo, whose broader phytochemical profile includes compounds that inhibit iNOS, COX-2, and NF-κB pathways; whether this specific flavone shares these properties has not been independently confirmed.
- **Antioxidant Context**: Co-occurring phytochemicals in the same Vitex negundo extracts, such as vitexdoin F, exhibit radical-scavenging activity; the antioxidant contribution of 4,5-diethyl-3'-ethoxy-pyroflavone specifically remains untested.
- **Antiparasitic Scaffold Interest**: Its pyroflavone backbone represents a structurally distinctive scaffold for antiparasitic drug discovery, making it of interest for medicinal chemistry optimization targeting lymphatic filariasis causative agents such as Brugia malayi and Wuchereria bancrofti.
- **Phytochemical Diversity Contribution**: As part of the complex polyphenolic matrix of Vitex negundo, it may contribute synergistically to the plant's overall bioactivity; however, isolated compound-specific contributions to multi-target effects remain speculative without fractionated bioassays.

How It Works

The precise molecular mechanism of 4,5-diethyl-3'-ethoxy-pyroflavone has not been elucidated in published literature; its antifilarial activity is described qualitatively as dose-dependent but without identification of specific molecular targets, receptor binding affinities, or enzyme inhibition data. Based on structural analogy to other antifilarial flavonoids, proposed mechanisms may include disruption of filarial microorganism energy metabolism, inhibition of glutathione-S-transferase isoforms critical to parasite detoxification, or interference with tubulin polymerization, though none of these have been experimentally confirmed for this specific compound. Related Vitex negundo flavonoids have demonstrated modulation of NF-κB signaling, suppression of inducible nitric oxide synthase (iNOS), and inhibition of cyclooxygenase-2 (COX-2), but direct extrapolation of these pathways to 4,5-diethyl-3'-ethoxy-pyroflavone is not supported by current data. The ethoxy substitution at the 3' position and ethyl groups at positions 4 and 5 of the pyroflavone core likely influence membrane permeability and metabolic stability relative to simpler flavone analogues, potentially enhancing bioavailability within filarial parasite tissue, but this remains hypothetical.

Scientific Research

The evidence base for 4,5-diethyl-3'-ethoxy-pyroflavone is extremely limited, consisting solely of preliminary preclinical findings cited in the context of Vitex negundo phytochemical characterization studies, most notably attributed to Rana et al., without confirmed peer-reviewed publication details or assigned PMIDs available in searchable databases at time of writing. No in vivo animal studies, pharmacokinetic analyses, or toxicological assessments have been published for this isolated compound. The antifilarial activity described is qualitative, characterized as 'significant' and dose-dependent, but lacks quantified endpoints such as IC50 values, percent parasite motility inhibition at defined concentrations, or comparative data against reference antifilarial drugs such as diethylcarbamazine or ivermectin. The overall evidence quality is at the lowest tier of preclinical research, and independent replication of the reported activity has not been documented in the literature.

Clinical Summary

No clinical trials of any phase have been conducted for 4,5-diethyl-3'-ethoxy-pyroflavone in human subjects. The compound has not progressed beyond early-stage phytochemical identification and qualitative bioactivity screening, and there are no registered trials in ClinicalTrials.gov, WHO ICTRP, or equivalent registries. No outcomes related to filarial infection clearance, microfilaremia reduction, adverse event profiles, or pharmacokinetic parameters in humans have been measured or reported. Confidence in any clinical application is absent, and any therapeutic claims for this compound in humans would currently be entirely unsupported by evidence.

Nutritional Profile

4,5-Diethyl-3'-ethoxy-pyroflavone is a pure phytochemical compound with no meaningful nutritional profile in the conventional macronutrient or micronutrient sense; it is not a source of calories, protein, fat, carbohydrates, vitamins, or essential minerals. As a flavone polyphenol (molecular formula estimated at C19H20O4 based on structural description; molecular weight approximately 312–316 g/mol), it possesses the aromatic ring systems characteristic of flavonoids that confer antioxidant electron-donating capacity in vitro, though quantified ORAC or DPPH values for this specific molecule are not reported. Its concentration within Vitex negundo plant material has not been quantified in published studies, and no data exist on oral bioavailability, first-pass metabolism, plasma half-life, or tissue distribution in any biological system. General flavonoid bioavailability considerations suggest extensive phase II conjugation (glucuronidation, sulfation) and colonic microbiome metabolism would likely apply, with oral bioavailability of the parent compound expected to be low, potentially below 10%, by analogy to structurally related flavones.

Preparation & Dosage

- **Isolation Method (Research Only)**: Extracted from dried Vitex negundo leaves, seeds, or roots using polar organic solvents (e.g., ethanol or methanol), followed by liquid-liquid partitioning and column chromatography (silica gel or reversed-phase HPLC) to yield the purified flavone; no standardized commercial extraction protocol exists.
- **No Supplement Form Available**: This compound is not available as a dietary supplement, nutraceutical, or pharmaceutical preparation; no capsule, tablet, tincture, or powder form has been commercialized.
- **No Established Human Dose**: No therapeutic dose, effective dose range, or tolerable upper intake level has been determined for humans; preclinical antifilarial assay concentrations are not directly translatable to human dosing.
- **Parent Plant Traditional Use**: Vitex negundo leaf powder has been used traditionally in Ayurveda at approximately 3–5 g/day in decoction or paste form for anti-inflammatory and antiparasitic purposes, but this reflects whole-plant use and not the isolated flavone.
- **Standardization**: No standardization percentage for 4,5-diethyl-3'-ethoxy-pyroflavone in any Vitex negundo extract product has been established or validated.

Synergy & Pairings

No evidence-based synergistic combinations have been studied for 4,5-diethyl-3'-ethoxy-pyroflavone. In the context of Vitex negundo phytochemistry, co-occurring compounds including labdane diterpenoids (with anti-inflammatory activity) and vitexdoin F (with antioxidant properties) may theoretically act synergistically to enhance the plant's overall antiparasitic and anti-inflammatory bioactivity matrix, though no fractionated or recombination studies have tested this hypothesis for this specific flavone. From a drug-discovery perspective, structural optimization of this pyroflavone scaffold in combination with established antifilarial agents such as diethylcarbamazine could represent a rational combinatorial approach to reduce resistance development, but this remains purely speculative.

Safety & Interactions

No safety data, toxicological assessments, LD50 determinations, or clinical adverse event reports exist for 4,5-diethyl-3'-ethoxy-pyroflavone as an isolated compound, making it impossible to define a safe dose range or characterize a side-effect profile at this time. As a constituent of Vitex negundo, indirect safety considerations from the parent plant are relevant: Vitex negundo preparations have been associated with emmenagogue and abortifacient effects in traditional accounts, and the plant is generally contraindicated during pregnancy and lactation; whether this flavone contributes to these effects is unknown. No specific drug interactions have been identified for this compound; however, flavonoid-class molecules broadly have the potential to modulate cytochrome P450 enzymes (particularly CYP1A2, CYP3A4) and P-glycoprotein transporters, which could theoretically alter the metabolism of co-administered pharmaceuticals, though this has not been studied for this specific molecule. Given the complete absence of human safety data, this compound should be considered investigational only and is not appropriate for self-administration or inclusion in consumer products.